Mesenteric Castleman disease: Two case reports and review of literature

Table 1 Clinical characteristics of three reported cases of Castleman disease complicated by secondary peripheral T-cell lymphoma

Ref.	Age/sex	Site of involvement	Initial diagnosis	Treatment	Interval to lymphoma transformation (year)	Type of lymphoma	Treatment of lymphoma	Prognosis
Liu et al[34], 2020	68/female	Neck	HV-MCD	Untreated	2	PTCL-U	CHOP, then relapse, chidamide-based chemotherapy	Survived
Park et al[38], 2013	37/male	Neck, axillae, and groin	PC-MCD	CHOP post steroid failure	4	PTCL	IVAM followed by BEAM and auto-PBSCT	Died
Qian et al[39], 2003	76/male	Bilateral submandibular areas and groin	PC-MCD	Steroids	1	PTCL	Untreated	Died

HV-MCD: Hyaline vascular multicentric Castleman disease; PC-MCD: Plasma cell multicentric Castleman disease; PTCL-U: Peripheral T-cell lymphoma of unspecified type; PTCL: Peripheral T-cell lymphoma; CHOP: Cyclophosphamide, adriamycin, vincristine, and dexamethasone; IVAM: Ifosfamide, etoposide, cytarabine, and methotrexate; BEAM: Bendamustine, etoposide, cytarabine, and melphalan; auto-PBSCT: Autologous peripheral blood stem cell transplantation.